GlassScriptPhysician profile
Grace Sierra
NPI 1285386151
$1,109.29
in general payments reported to CMS, 2019-2025
12 companies · $526 in 2025
The $526 reported for 2025 was more than what 76% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $22.31 · 2023: $267 · 2024: $294 · 2025: $526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $990 · Education: $96.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $990.48 |
| Education | $96.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $250.66 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Merck Sharp & Dohme LLC | $241.65 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Daiichi Sankyo INC. | $130.06 | 2025 | Enhertu |
| Myriad Genetic Laboratories, INC. | $124.12 | 2023-2024 | Myrisk |
| Novartis Pharmaceuticals Corporation | $92.99 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $69.64 | 2024-2025 | Enhertu |
| Stemline Therapeutics INC. | $59.46 | 2025 | Orserdu |
| Tempus Ai, INC | $40.42 | 2024 | Xt Cdx |
| Tersera Therapeutics LLC | $31.89 | 2024 | Zoladex |
| Gilead Sciences, INC. | $26.29 | 2025 | |
| Ethicon US, LLC | $22.31 | 2022 | |
| Caris Mpi, INC. | $19.80 | 2025 | Mi Cancer Seek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Sierra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.